A new therapeutic target in Alzheimer's disease treatment: Attention to butyryloholinesterase

Current Medical Research and Opinion

Volumn 17, Issue 3, 2001, Pages 159-165

  Greig, N H ^a   Utsuki, T ^a   Yu, Q S ^a   Zhu, X ^a   Holloway, H W ^a   Perry, T ^a   Lee, B ^a   Ingram, D K ^a   Lahiri, D K ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Amyloid; Butyrylcholinesterase; Cholinergic; Cognition; Inhibition

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BISNORCYMSERINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYMSERINE; MF 8622; PHENETHYLCYMSERINE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; HUMAN; SYNAPSE;

ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 0035661483     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990152673800     Document Type: Article

References (46)

1. Alzheimer's disease
2. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease
3. Fractional diffusion limited component of reactions catalyzed by acetylcholinesterase
4. Metabolic relations between glia and neurons studied in single cells
5. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
6. Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
7. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein
8. Acetylcholinesterase: Enzyme structure, reaction dynamics and virtual transition states
9. The cholinesterases: From genes to proteins
10. Postnatal developmental delay and supersensitivity to organophosphate in gene targeted mice lacking acetylcholinesterase
11. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse
12. Cholinesterase inhibitors: From the calabar bean to Alzheimer therapy
13. Alzheimer disease, from molecular biology to therapy
14. The effect of MF-8622: A selective BuChE inhibitor
15. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo
16. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo
17. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates
18. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system
19. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms
20. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
21. Changes in brain cholinesterases in senile dementia of Alzheimer type
22. Pseudocholinesterase staining in the primary visual pathway of the macaque monkey
23. Distribution of butyrylcholinesterase in human amygdala and hippocampal formation
24. Butyrylcholinesterase in the life cycle of amyloid plaques
25. Butyrylcholinesterase alters the aggregation state of β-amyloid
26. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
27. Synergy between the genes for butyrylcholinesterase K variant apolipoprotein E4 in late-onset confirmed Alzheimer's disease
28. Treating AD-related dementias: Results in dementia with Lewy bodies
29. The synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease
30. Methyl analogues of the experimental Alzheimer drug, phenserine: Synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action
31. Butyrylcholinesterase (BuChE) inhibitors for the treatment of Alzheimer's disease
32. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase
33. The experimental Alzheimer drug phenserine: Preclinical pharmacodynamics and kinetics in the rat
34. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease
35. Phenserine regulates translation of amyloid precursor protein mRNA by a putative interleukin-1 responsive element: A target for drug development
36. Induction, secretion and pharmacological regulation of β-APP in animal model systems
37. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer's patients
38. AChE and BuChE activities in CSF of mild AD patients following 12 months of rivastigmine treatment
39. Improved cognition and plasma ChE inhibition in AD patients receiving rivastigmine for one year: Differential effects across time
40. Improved cortical glucose metabolism in AD patients treated with rivastigmine for one year